首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1965875

合成幹細胞市場－全球產業規模、佔有率、趨勢、機會與預測：按應用、地區和競爭格局分類，2021-2031年

Synthetic Stem Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Cardiovascular Diseases, Neurological Disorders, Other Applications ), By Region & Competition, 2021-2031F

出版日期: 2026年01月19日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球合成幹細胞市場預計將從 2025 年的 1,658 萬美元成長到 2031 年的 3,028 萬美元，複合年成長率達到 10.56%。

該市場的特點是開發生物工程系統，包括基於聚合物的微粒，旨在模擬天然幹細胞的旁分泌治療效應，而無需依賴生物組織。該領域的關鍵促進因素包括消除活細胞療法固有的致瘤風險，以及無需複雜低溫運輸儲存的穩定儲存製劑所帶來的物流優勢。這些優勢解決了傳統再生醫學中面臨的主要安全性和擴充性挑戰，使合成替代方案成為治療慢性退化性疾病的實用解決方案。

市場概覽
預測期	2027-2031
市場規模：2025年	1658萬美元
市場規模：2031年	3028萬美元
複合年成長率：2026-2031年	10.56%
成長最快的細分市場	心血管疾病
最大的市場	北美洲

儘管這些非生物模擬物具有許多營運優勢，但市場在監管分類方面仍面臨許多挑戰。監管機構難以明確界定這些非生物模擬物究竟屬於醫療設備、生物製藥或化合物產品。這種模糊性造成了不確定性，阻礙了核准流程，但此類創新的融資環境仍有利。根據再生醫學聯盟預測，到2025年，再生醫學領域的整體投資將成長30%，凸顯了支持包括合成應用在內的下一代治療技術的強勁資金流向。

市場促進因素

推動市場發展的主要因素是再生醫學領域研發投資的激增。這為將合成幹細胞技術從理論概念轉化為臨床應用產品提供了必要的資金。這個穩健的金融生態系統幫助生物技術公司克服了臨床前檢驗和生產規模化等成本高昂的階段，直接滿足了推出新型非生物療法所需的資源。例如，根據《歐洲生物技術雜誌》2025年6月報道，英國政府宣布了一項新的產業戰略，承諾將在生物技術領域投入3.8億英鎊。此舉旨在降低早期研發風險，並鼓勵私部門參與合成再生醫學解決方案的商業化，從而避免生物供應鏈的波動。

此外，奈米技術和合成生物學的進步正在從根本上改變市場格局，提高了生物工程細胞模擬物的精確度和有效性。這些技術突破使得建構能夠精確複製複雜旁分泌訊號的聚合物基系統成為可能，有效降低了細胞療法中常見的批次間差異。例如，英國政府科技部落格在2025年6月報道稱，英國研究與創新署（UKRI）投資1億英鎊建立了六個“工程生物學任務中心”，以加速該技術在醫學領域的應用。研究專業新聞也在2024年11月通報稱，UKRI追加投資580萬英鎊，以支持產業發展，鞏固合成平台作為治療方法研發核心要素的重要性。

市場挑戰

全球合成幹細胞市場面臨的一大挑戰是監管分類的嚴重模糊性。由於這些生物工程系統的功能與生物製藥類似，但卻由聚合物等合成材料構成，監管機構難以確定它們究竟應被明確歸類為醫療設備、藥品或生物製藥。這種不確定性迫使製造商必須應對複雜且不規範的核准流程，例如美國的指定申請程序和歐洲類似的混合評估。因此，企業必須產生大量額外的安全性和有效性數據，以滿足多個監管機構的不同標準，從而顯著延長研發週期並增加成本。

由於缺乏明確的法規結構，大量資金和技術專長從研發轉移到合規方面，直接阻礙了市場擴張。這些分類爭議造成的資源浪費正在減緩可儲存再生醫學治療方法的商業化。根據2024年歐洲醫療技術協會（MedTech Europe）的一項調查，超過70%的先進醫療技術製造商表示，應對不斷演變且複雜的監管合規框架需要投入額外的內部資源。這種營運瓶頸限制了能夠進入商業化階段的合成幹細胞產品數量，儘管市場對該領域有著濃厚的興趣，但實際上卻抑制了該領域的整體成長。

市場趨勢

合成幹細胞與3D生物列印技術的日益融合正在革新組織工程，使其能夠建構複雜且功能強大的支架材料，從而精確模擬天然細胞外基質。這一趨勢的重點在於將生物工程微粒整合到可列印生物墨水中，以提高結構穩定性並精確控制生長因子的釋放，這對於支持血管生成和器官再生至關重要。製造商正在加速這些協同平台的商業化進程，以克服傳統水凝膠在機械和物流方面的限制。例如，BICO集團在2025年2月公佈，其2024會計年度的年度淨銷售額達到19.463億瑞典克朗，這反映了圍繞合成組織模型所必需的生物融合技術的活躍發展。

同時，在消費者對符合倫理規範、非動物性生物活性成分日益成長的需求推動下，藥用化妝品（化妝品與藥品相結合）和抗衰老配方市場正穩步擴張。合成幹細胞培養物，特別是植物來源或人工設計的仿生外泌體的幹細胞培養物，被廣泛應用於高性能護膚品的研發，這些產品能夠提供可重複的效果，且避免了生技藥品相關的監管和穩定性問題。這些合成活性成分因其保護皮膚幹細胞和促進膠原蛋白生成的能力而備受推崇。為了佐證該領域的商業性潛力，歐洲化妝品協會（Cosmetics Europe）在2025年6月發布的報告顯示，2024年歐洲美容和個人護理市場零售額將達到1040億歐元，凸顯了這些先進生物技術配方可應用的巨大市場規模。

The Global Synthetic Stem Cells Market is projected to expand from USD 16.58 Million in 2025 to USD 30.28 Million by 2031, achieving a compound annual growth rate of 10.56%. This market is characterized by the creation of bioengineered systems, including polymer-based microparticles, which are designed to mimic the therapeutic paracrine effects of natural stem cells without relying on living biological tissue. Key drivers fueling this sector include the elimination of tumorigenic risks inherent in live cell therapies and the logistical benefits of shelf-stable formulations that avoid complex cold-chain storage. These advantages address major safety and scalability issues in traditional regenerative medicine, establishing synthetic alternatives as a viable solution for treating chronic degenerative diseases.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 16.58 Million
Market Size 2031	USD 30.28 Million
CAGR 2026-2031	10.56%
Fastest Growing Segment	Cardiovascular Diseases
Largest Market	North America

Despite these operational benefits, the market encounters significant obstacles regarding regulatory classification, as agencies face difficulties in definitively categorizing these non-living mimics as medical devices, biologics, or combination products. This ambiguity creates uncertainty that can impede approval processes; however, the financial landscape remains favorable for such innovation. According to the Alliance for Regenerative Medicine, the broader regenerative medicine sector saw a 30 percent increase in investment in 2025, highlighting the strong flow of capital available to support next-generation therapeutic technologies, including synthetic applications.

Market Driver

A primary catalyst for the market is the surge in research and development investment for regenerative medicine, which provides the essential capital to advance synthetic stem cell technologies from theoretical concepts to viable clinical products. This strong financial ecosystem supports biotechnology firms in navigating the expensive stages of preclinical validation and manufacturing scale-up, directly addressing the resources needed to launch novel non-living therapeutics. For example, European Biotechnology Magazine reported in June 2025 that the UK government announced a new industrial strategy committing £380 million to engineering biology, a move that de-risks early-stage development and encourages private sector involvement in commercializing synthetic regenerative solutions that avoid biological supply chain volatility.

Furthermore, advancements in nanotechnology and synthetic biology are fundamentally transforming the market by improving the precision and efficacy of bioengineered cell mimics. These technical breakthroughs enable the creation of polymer-based systems that replicate complex paracrine signaling with high consistency, effectively reducing the batch-to-batch variability common in cellular therapies. Illustrating this trend, the Government Science and Engineering Blog noted in June 2025 that UKRI invested £100 million in six Engineering Biology Mission Hubs to accelerate technology application in health sectors. Additionally, Research Professional News reported in November 2024 that UKRI invested another £5.8 million to support sector growth, ensuring synthetic platforms remain central to therapeutic development.

Market Challenge

The principal challenge obstructing the Global Synthetic Stem Cells Market is the profound ambiguity regarding regulatory classification. Because these bioengineered systems function similarly to biologics but are constructed from synthetic materials like polymers, regulatory bodies struggle to categorize them definitively as medical devices, drugs, or biologics. This uncertainty compels manufacturers to navigate complicated, non-standardized approval routes, such as the Request for Designation process in the United States or similar hybrid assessments in Europe. Consequently, companies are required to generate extensive additional safety and efficacy data to satisfy the divergent standards of multiple regulatory centers, which significantly extends development timelines and increases costs.

This lack of a clear regulatory framework directly hinders market expansion by diverting capital and technical expertise from research and development toward managing compliance hurdles. The resource drain resulting from these classification disputes slows the commercialization of shelf-stable regenerative treatments. According to MedTech Europe in 2024, over 70 percent of advanced medical technology manufacturers indicated that navigating such evolving and complex regulatory compliance frameworks necessitated the allocation of additional internal resources. This operational bottleneck restricts the volume of synthetic stem cell products reaching the commercial stage, effectively stalling the sector's overall growth despite strong financial interest.

Market Trends

The increasing integration of synthetic stem cells with 3D bioprinting technologies is revolutionizing tissue engineering by allowing for the fabrication of complex, functional scaffolds that accurately simulate natural extracellular matrices. This trend focuses on embedding bioengineered microparticles into printable bio-inks to improve structural stability and provide precise control over growth factor release, which is essential for supporting vascularization and organ regeneration. Manufacturers are increasingly commercializing these synergistic platforms to address the mechanical and logistical limitations of traditional hydrogels. As evidence of this industrial scale, BICO Group reported in February 2025 that their full-year net sales reached SEK 1,946.3 million for 2024, reflecting the substantial activity surrounding the bioconvergence technologies necessary for these synthetic tissue models.

Concurrently, the market is witnessing a robust expansion into cosmeceutical and anti-aging formulations, driven by rising consumer demand for ethical, non-animal-derived bioactive ingredients. Synthetic stem cell cultures, particularly those derived from plant sources or engineered biomimetic exosomes, are being widely adopted to create high-performance skincare products that offer reproducible potency without the regulatory and stability issues associated with human-derived biologics. These synthetic actives are valued for their ability to protect skin stem cells and stimulate collagen production. Underscoring the commercial potential of this sector, Cosmetics Europe reported in June 2025 that the European beauty and personal care market generated retail sales of €104 billion in 2024, highlighting the vast landscape available for these advanced biotechnological formulations.

Key Market Players

ThermoGenesis Holdings Inc.
Sangamo Therapeutics, Inc.
Pluri Inc
Gamida Cell Ltd.
Brainstorm Cell Therapeutics Ltd.
Vericel Corporation
Lisata Therapeutics, Inc.
Cellular Biomedicine Group Inc.
Cytori Therapeutics Inc.
Vistagen Therapeutics, Inc.

Report Scope

In this report, the Global Synthetic Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Synthetic Stem Cells Market, By Application

Cardiovascular Diseases
Neurological Disorders
Other Applications (Cancers, Wounds and Injuries, Musculoskeletal Disorders, Blood disorders)

Synthetic Stem Cells Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Synthetic Stem Cells Market.

Available Customizations:

Global Synthetic Stem Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Synthetic Stem Cells Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Application (Cardiovascular Diseases, Neurological Disorders, Other Applications (Cancers, Wounds, Injuries, Musculoskeletal Disorders, Blood disorders))
- 5.2.2. By Region
- 5.2.3. By Company (2025)
5.3. Market Map

6. North America Synthetic Stem Cells Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Application
- 6.2.2. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Synthetic Stem Cells Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Application
- 6.3.2. Canada Synthetic Stem Cells Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Application
- 6.3.3. Mexico Synthetic Stem Cells Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Application

7. Europe Synthetic Stem Cells Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Application
- 7.2.2. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Synthetic Stem Cells Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Application
- 7.3.2. France Synthetic Stem Cells Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Application
- 7.3.3. United Kingdom Synthetic Stem Cells Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Application
- 7.3.4. Italy Synthetic Stem Cells Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Application
- 7.3.5. Spain Synthetic Stem Cells Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Application

8. Asia Pacific Synthetic Stem Cells Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Application
- 8.2.2. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Synthetic Stem Cells Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Application
- 8.3.2. India Synthetic Stem Cells Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Application
- 8.3.3. Japan Synthetic Stem Cells Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Application
- 8.3.4. South Korea Synthetic Stem Cells Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Application
- 8.3.5. Australia Synthetic Stem Cells Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Application

9. Middle East & Africa Synthetic Stem Cells Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Application
- 9.2.2. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Synthetic Stem Cells Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Application
- 9.3.2. UAE Synthetic Stem Cells Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Application
- 9.3.3. South Africa Synthetic Stem Cells Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Application

10. South America Synthetic Stem Cells Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Application
- 10.2.2. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Synthetic Stem Cells Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Application
- 10.3.2. Colombia Synthetic Stem Cells Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Application
- 10.3.3. Argentina Synthetic Stem Cells Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Synthetic Stem Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. ThermoGenesis Holdings Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Sangamo Therapeutics, Inc.
15.3. Pluri Inc
15.4. Gamida Cell Ltd.
15.5. Brainstorm Cell Therapeutics Ltd.
15.6. Vericel Corporation
15.7. Lisata Therapeutics, Inc.
15.8. Cellular Biomedicine Group Inc.
15.9. Cytori Therapeutics Inc.
15.10. Vistagen Therapeutics, Inc.